MedTrace Logo

TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

NCT06487663 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-07-05

No results posted yet for this study

Summary

This study will evaluate the efficacy and safety of TACE combined with immune checkpoint inhibitors to treat unresectable hepatocellular carcinoma.

Conditions

  • Hepatocellular Carcinoma Non-resectable
  • Cholangiocarcinoma Non-resectable
  • Liver Metastases
  • Liver Malignant Tumors

Interventions

PROCEDURE

TACE with ICI

Transcatheter hepatic artery chemoembolization and immune checkpoint inhibitors

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-27
Primary Completion
2025-10-27
Completion
2026-10-27

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06487663 on ClinicalTrials.gov